Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
Anavex Life Sciences (Nasdaq: AVXL) announced that Dr. Marwan Noel Sabbagh, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board, delivered an oral presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders in Abu Dhabi, UAE (April 18-20, 2025).
The presentation, titled 'Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial,' was part of a conference that brought together healthcare professionals, researchers, and advocates from the MENA region, USA, and Europe to discuss Alzheimer's disease and related disorders, with a focus on region-specific healthcare delivery.
Anavex Life Sciences (Nasdaq: AVXL) ha annunciato che il Dr. Marwan Noel Sabbagh, Professore di Neurologia presso il Barrow Neurological Institute e Presidente del Comitato Scientifico di Anavex, ha tenuto una presentazione orale al 9° Congresso Internazionale sulla Malattia di Alzheimer e Disturbi Correlati ad Abu Dhabi, Emirati Arabi Uniti (18-20 aprile 2025).
La presentazione, intitolata 'Oral Blarcamesine: Nuovo Meccanismo per la Malattia di Alzheimer - Ripristino dell'Autofagia tramite Attivazione Upstream di SIGMAR1 - Efficacia Clinica nello Studio di Fase IIb/III,' faceva parte di una conferenza che ha riunito professionisti sanitari, ricercatori e sostenitori provenienti dalla regione MENA, dagli USA e dall'Europa per discutere della malattia di Alzheimer e dei disturbi correlati, con un focus sulla gestione sanitaria specifica per la regione.
Anavex Life Sciences (Nasdaq: AVXL) anunció que el Dr. Marwan Noel Sabbagh, Profesor de Neurología en el Barrow Neurological Institute y Presidente del Consejo Asesor Científico de Anavex, ofreció una presentación oral en la 9ª Conferencia Internacional sobre la Enfermedad de Alzheimer y Trastornos Relacionados en Abu Dhabi, Emiratos Árabes Unidos (18-20 de abril de 2025).
La presentación, titulada 'Oral Blarcamesine: Nuevo Mecanismo para la Enfermedad de Alzheimer - Restauración de la Autofagia mediante la Activación Upstream de SIGMAR1 - Eficacia Clínica en el Ensayo de Fase IIb/III,' formó parte de una conferencia que reunió a profesionales de la salud, investigadores y defensores de la región MENA, EE. UU. y Europa para debatir sobre la enfermedad de Alzheimer y trastornos relacionados, con un enfoque en la atención sanitaria específica de la región.
Anavex Life Sciences (나스닥: AVXL)는 바로 신경학 연구소의 신경학 교수이자 Anavex 과학 자문 위원회 의장인 Dr. Marwan Noel Sabbagh가 아랍에미리트 아부다비에서 열린 제9회 알츠하이머병 및 관련 장애 국제 학술대회(2025년 4월 18-20일)에서 구두 발표를 했다고 발표했습니다.
'Oral Blarcamesine: 알츠하이머병의 새로운 기전 - 상류 SIGMAR1 활성화를 통한 자가포식 복원 - 임상 효능 2b/3상 시험'이라는 제목의 발표는 MENA 지역, 미국, 유럽의 의료 전문가, 연구자, 옹호자들이 모여 알츠하이머병 및 관련 장애를 논의하고 지역별 의료 제공에 중점을 둔 학술대회의 일부였습니다.
Anavex Life Sciences (Nasdaq : AVXL) a annoncé que le Dr Marwan Noel Sabbagh, professeur de neurologie à l'Institut neurologique Barrow et président du comité consultatif scientifique d'Anavex, a présenté une communication orale lors de la 9e Conférence internationale sur la maladie d'Alzheimer et les troubles apparentés à Abou Dhabi, Émirats arabes unis (18-20 avril 2025).
La présentation, intitulée « Oral Blarcamesine : nouveau mécanisme pour la maladie d'Alzheimer – restauration de l'autophagie via l'activation en amont de SIGMAR1 – efficacité clinique dans l'essai de phase IIb/III », faisait partie d'une conférence rassemblant des professionnels de santé, chercheurs et défenseurs de la région MENA, des États-Unis et d'Europe pour discuter de la maladie d'Alzheimer et des troubles associés, avec un accent sur la prise en charge sanitaire spécifique à la région.
Anavex Life Sciences (Nasdaq: AVXL) gab bekannt, dass Dr. Marwan Noel Sabbagh, Professor für Neurologie am Barrow Neurological Institute und Vorsitzender des Wissenschaftlichen Beirats von Anavex, einen Vortrag auf der 9. Internationalen Konferenz über Alzheimer-Krankheit und verwandte Störungen in Abu Dhabi, VAE (18.-20. April 2025), gehalten hat.
Der Vortrag mit dem Titel „Oral Blarcamesine: Neuer Mechanismus bei Alzheimer-Krankheit – Wiederherstellung der Autophagie durch upstream SIGMAR1-Aktivierung – Klinische Wirksamkeit in der Phase-IIb/III-Studie“ war Teil einer Konferenz, die Gesundheitsfachkräfte, Forscher und Fürsprecher aus der MENA-Region, den USA und Europa zusammenbrachte, um Alzheimer und verwandte Störungen zu diskutieren, mit Fokus auf regionalspezifische Gesundheitsversorgung.
- None.
- None.
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex’s Scientific Advisory Board gave an oral presentation titled, “Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial” at the 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East.
The ‘9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East’ was held April 18-20, 2025 in Abu Dhabi, United Arab Emirates (UAE). The meeting convened clinicians including neurologists, psychiatrists, and geriatricians, nurses, public health workers, researchers, social workers, students, caregivers, and community advocates from the Middle East and North Africa (termed the MENA region), USA, Europe and other countries with an interest in epidemiology, clinical/research, medicine, basic science, and healthcare advocacy related to Alzheimer’s disease and related disorders (ADRD) in the region. Specifically, an emphasis on region specific healthcare delivery were addressed.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
What was presented at the 2025 Middle East Alzheimer's Conference regarding AVXL's Blarcamesine?
Where and when was AVXL's latest Alzheimer's research presented in 2025?
Who presented Anavex's (AVXL) Alzheimer's drug research in Abu Dhabi?
What is the mechanism of action for AVXL's Blarcamesine in Alzheimer's treatment?
